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Abstract: Antibody-dependent enhancement (ADE) has been proposed as a mechanism to 
explain dengue hemorrhagic fever (DHF) in the course of a secondary dengue infection. 
Very recently, Dejnirattisai et al., 2010 [1], published an important article supporting the 
involvement of anti-prM antibodies in the ADE phenomenon. The complexity of ADE in 
the context of a secondary dengue infection is discussed here. 
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1. Introduction 
A rapid increase in dengue reports has been observed in the last three decades. Today, dengue 
infections are a serious cause of morbidity and mortality in most tropical and subtropical regions of the 
world: an estimated 50–100 million people are infected annually and over 2.5 billion people live in 
endemic  areas;  and  more  than  100  countries  are  at  risk  for  dengue  transmission.  The  disease  is 
endemic in Asia, the Pacific, the Americas, Africa and the Middle East [2,3]. 
Dengue is caused by four antigenically related viruses (DENV 1-4) within the family Flaviviridae, 
genus Flavivirus. These are transmitted to humans by Aedes mosquito bites, and Aedes aegypti is the 
main vector. The genome of these enveloped single-strand positive-polarity RNA viruses codes for 
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three  structural  proteins  (capsid  C,  membrane,  M,  and  the  envelope,  E)  and  seven  non-structural 
proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) [4].  
Two  types  of  virions  are  recognized:  mature  extracellular  virions  contain  M  protein,  while 
immature  intracellular  virions  contain  prM,  which  is  proteolytically  cleaved  during  maturation  to  
yield M protein. 
The envelope of the virus contains the viral surface proteins E and M. The E glycoprotein has 
important functional roles in virus attachment to cells and fusion with membranes, and is the major 
target for neutralizing antibody. It contains the main epitopes recognized by neutralizing antibodies 
(virus-specific  and  cross-reactive  epitopes)  [5,6].  This  protein  has  three  structural  and  functional 
domains: domain II contains the internal fusion peptide (responsible for the fusion of flaviviruses to 
their target cells) and domain III the cellular receptor-binding motifs [7,8]. Domains I and III contain 
predominantly  subcomplex-  and  type-specific  epitopes,  whereas  domain  II  contains  the  major 
flavivirus group and subgroup cross-reactive epitopes [9–11].  
M protein may be found in two forms. In cell-associated (immature) virions, prM (the precursor of 
M  protein)  is  observed,  which  forms  a  heterodimer  with  the  E  protein  (prM-E  heterodimer). 
Apparently, prM serves as a chaperone for the E protein, protecting it from irreversible inactivation 
during  transport  of  virions  to  the  cell  surface  in  acidic  post-Golgi  vesicles  [12,13].  Through  this 
association, prM participates in the viral assembly and budding into the lumen of the endoplasmic 
reticulum.  Intracellular  virions  remain  non-infectious  until  release  when  they  are  converted  to 
infectious form through the cleavage of prM into the soluble pr peptide and the particle associated M 
protein by a host-cell-derived furin-like protease [14]. 
Uncleaved prM prevents the E protein from undergoing the structural changes that are required for 
low-pH-induced  membrane  fusion  of  DENV.  Therefore,  fully  immature  DENV  is  essentially  
non-infectious [15]. Depending on the extent of prM cleavage, the extracellular particles may contain 
varying proportions of prM and M. Levels of around 30% of prM containing immature particles have 
been reported in DENV infected cells [16, 17]. The charged residues surrounding the furin consensus 
sequence at the prM cleavage junction could partially explain lower or higher cleavage efficiency; in 
addition, structural differences inherent to flaviviruses at prM junction affect prM cleavability [18].  
2. Dengue Hemorrhagic Fever, Secondary Infection and Antibody-Dependent Enhancement 
Dengue infection can be asymptomatic or present in two clinical forms of illness, dengue fever (DF) 
and the more severe dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Plasma leakage, 
hemorrhage and thrombocytopenia characterize DHF/DSS [19,20].  
Single-serotype natural infections result in lifelong immunity to the infecting serotype but only 
short-term  cross-protection  against  heterotypic  serotypes  [21].  The  humoral  response  to  dengue 
infection is important for controlling infection and virus dissemination. Despite antigenic relatedness 
of  viruses  in  the  dengue  complex,  two  or  more  serotypes may  sequentially  infect one  individual. 
Specific neutralizing IgG antibody against the infecting DENV lasts decades, while cross-reactive 
neutralizing activity declines over time [22,23]. Preliminary reports also suggest that in human beings 
there is a continuous selection process of populations of dengue-virus neutralizing-antibodies with 
increasing homologous reactivity and concurrent decrease in heterotypic cross reactions [24].  Viruses 2010, 2                         
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Early studies in Thailand recognized that DHF/DSS peaked in two populations: first-time infected 
infants born to dengue-immune mothers and children who had experienced a mild or asymptomatic 
dengue  infection  and  become  secondarily  infected  by  a  different  dengue  serotype  [25,26].  These 
studies suggested that DHF/DSS is 15-80 times more frequent in secondary infections than in primary 
ones, and that up to 99% of DHF cases reveal heterotypic antibodies to the dengue serotype causing 
the DHF [27].  
These first observations were confirmed in a different setting. The DENV 2 epidemic of 1981 
(preceded by a mild epidemic of DENV 1 in 1977) reported in Cuba, supported secondary infection as 
a main risk factor for the severe forms of dengue infection. In this epidemic of more than 300,000 
cases, 10,000 severe and very severe cases and 158 fatalities (101 children), secondary infection in the 
sequence DENV 1/DENV 2 was demonstrated in 98% of the DHF/DSS cases [28–30]. In addition, 
DHF/DSS  did  not  occur  in  children  of  1-2  years.  They  were  born  after  the  1977  epidemic  and, 
consequently, in 1981, they were at risk only of primary DENV infection [29]. More than 20 years 
after the DENV 1 epidemic, secondary infection as a main risk factor for DHF/DSS was confirmed 
again in the Cuban epidemics of 1997 (DENV 2) and 2001-02 (DENV 3) [31–35].  
To  explain  the  association  of  secondary  infection  to  severe  illness,  Antibody-Dependent 
Enhancement (ADE) was proposed as the immune system’s mechanism to enhance viral pathogenesis. 
ADE has been described for several viruses including DENVs, measured by in vitro enhancement of 
cell  infection  [36–38].  Also,  monkeys  passively  immunized  concurrently  with  a  DENV  infection 
developed  a  higher  viremia  than  control  animals  [39].  More  recently,  Goncalvez  et  al.  [40] 
demonstrated a significant increase of DENV 4 viremia titers in monkeys passively immunized with 
transferred dilutions of an anti-dengue humanized monoclonal antibody [40].  
In humans, indirect evidence of ADE has been reported. ADE was observed in vitro in sera from 
mothers whose infants developed DHF after a primary dengue infection [41]. This study demonstrated 
that maternal antibody to DENV declines at a constant rate and passes in time through three functional 
states: neutralization, enhancing virus growth and antibody degradation. This early study suggested 
that as anti-dengue antibody to a first infection wanes, some individuals will experience an interval 
during  which  their  antibody  level  will  drop  below its  protective capacity,  acquiring the power  to 
enhance infection. In another study, Kliks et al. [42] reported that undiluted pre-infection sera from 
children who developed DHF were more likely to show enhancement of the dengue virus infection 
than pre-infection sera of children with an asymptomatic secondary infection.  
Evidence  suggests  that  enhancing  and  cross-reactive  neutralizing  antibodies  regulate  dengue 
epidemics  and  disease  severity.  In  this  sense,  epidemiological  and  serological  observations  made 
during the Cuban dengue epidemics support the role of secondary infection and ADE even 20 or more 
years after primary dengue infection. A marked increase in severity associated with the longer of the 
two  intervals  (20  years  versus  four  years)  between  an  initial  DENV1  infection  and  a  secondary 
DENV 2 (Asian genotype) infection has been reported [43]. In addition, some sequences of infection 
such as DENV 1 followed by DENV 2, and DENV 1 followed by DENV 3 have been associated with 
greater disease severity [44,45].  Viruses 2010, 2                         
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3. The Antibody-Dependent Enhancement Phenomenon 
ADE  occurs  when  antibody-virus  complexes  are  internalized  into  cells  via  FcRs  resulting  in 
infection of a higher number of target cells, which may lead to higher viral production. Cross-reactive 
antibodies lacking neutralizing activity are induced during a primary dengue infection. In secondary 
infection, these antibodies bind to the second infecting virus. Increased viral production has typically 
been interpreted to be the result of an increased number of infected Fc-R-bearing cells and possibly 
the result of an accelerated rate of internalization and cell infection by immune-complexes [46–48]. A 
higher viremia in infected patients and consequent greater severity has been hypothesized [49]. Studies 
reported  by  Vaughn  et  al.  and  Libraty  et  al.  observed  a  higher  viremia  and  NS1  antigenemia  in 
children with DHF than in those with DF [50,51]. Also in Taiwanese patients it was observed that 
dengue RNA titers even after defervescence, correlated with disease severity [52]. In a more recent 
study, Cameron et al. reported heterogeneity in viremia and NS1 antigenemia in Vietnamese infants 
with DHF in the course of their primary DENV infection; however these determinations were made at 
the  time  of  hospital  admission.  They  also  found  that  these  infants  experienced  DHF  when  the 
maternally-derived neutralizing antibody titer had declined to <1:20 [53]. 
A complementary mechanism to higher viremia explaining disease severity as a consequence of 
ADE may be that FcR-mediated entry suppresses the antiviral immune response. An in vitro study 
with Ross River virus showed that viral entry via the FcR pathway could suppress antiviral genes and 
enhance  IL-10  production,  while  entry  via  the  normal  mechanism  does  not  change  the  antiviral 
environment [54]. In the case of dengue, it has been reported that infection of THP-1 cells via FcR also 
suppresses transcription and production of IL-12, IFN, TNF and NO, but enhances the expression of 
anti-inflammatory  cytokines  [55]  with  a  milieu  change  favorable  to  viral  replication.  These 
observations suggest that ADE of DENV infection not only facilitates the virus entry process but also 
could modify innate and adaptive intracellular antiviral mechanisms [55].  
Studies using monoclonal antibodies have demonstrated that enhancing antibodies are directed to E 
and prM proteins [56]. Although both proteins seem to be involved in neutralization and the ADE 
mechanism, more studies have been designed to evaluate the role of E protein. Greater understanding 
of the antibody-neutralization mechanisms could shed light on their likelihood of promoting ADE.  
4. The Neutralization Mechanism 
Flavivirus neutralization is a multiple-hit phenomenon requiring engagement by more than one 
antibody. Neutralization occurs when the number of antibodies bound to an individual virion exceeds a 
required  threshold,  antibody  affinity  and  accessibility  of  epitopes  on  virus  particles  playing  an 
important  role  [57].  Neutralizing  antibodies  directed  mostly  to  E  protein  inhibit  viral  attachment, 
internalization and/or replication within the cell [58]. These E-specific antibodies appear to be pivotal, 
mediating homologous protection against dengue reinfection; however, in mice, prM vaccine has also 
been shown to protect against the lethal DENV challenge [59]. 
Neutralization  at  low  occupancy  requires  lower  antibody  concentrations  and  can  occur  with  
lower-affinity  antibodies,  while  those  antibodies  specific  to  poorly  accessible  epitopes  require 
relatively  high  concentrations.  Most  epitopes  have  the  capacity  to  elicit  antibodies  capable  of 
promoting ADE [60]; however, antibodies specific to poorly accessible epitopes are more likely to Viruses 2010, 2                         
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promote ADE over a wide range of concentrations [61,62]. Recently, Lok et al. [63] showed that a 
partially  occluded  epitope  may  become  available  to  antibody  binding  under  certain  conditions, 
suggesting that the virus is in dynamic motion making hidden epitopes briefly available [63]. 
Despite  the  large  body  of  work  with  mouse  monoclonal  antibodies,  little  has  been  done  to 
characterize the binding properties of human dengue immune sera and to understand the relationship 
between human antibody binding, neutralization and ADE [64]. Recent studies have proposed that the 
major cross-reactive and serotype-specific neutralizing epitopes targeted by human immune sera are 
inter-domain epitopes and/or located outside of domain III of E protein [40,65]. Wahala et al. observed 
that,  unexpectedly,  domain  III-binding  antibodies  play  a  minor  role  in  DENV  neutralization.  In 
addition, in another report these authors suggest that type-specific epitopes on domain III are not 
conserved  between  strains  of  DENV3  [66].  Previous  investigations  support  large  differences  in 
neutralization titers when comparing different genotypes of the same virus [67,68].  
5. Potential Role of Immature DENV in Antibody-Dependent Enhancement 
Recently, Dejnirattisai et al. [1] generated a panel of human monoclonal antibodies to DENV. They 
observed that (a) antibodies to prM were a major component of the response, highly cross-reactive 
among the dengue serotypes, and (b) these antibodies have potent ADE activity and low neutralization 
capacity. Considering these results, the authors propose that partial cleavage of prM reduces antigen 
density availability for viral neutralization, leaving the viruses susceptible to ADE by antibody to prM.  
Previously,  a  host-protective  effect  of  anti-prM  was  reported  for  DENV;  however,  how  these 
antibodies  would  exert  their  effect  was  not  clear  [18,59,69–71].  It  has  been  proposed  that  weak 
neutralization of dengue infectivity by some anti prM monoclonal antibodies and anti-prM peptide sera 
could be due to their cross-reactivity with E protein [18,70,71]. However, similar levels of enhancing 
activity by strongly enhancing anti-E monoclonal antibodies have been previously reported [56,72]. 
Some studies report enhancement of infection presumably due to the presence of uncleaved prM in 
virus preparations, but also with DENV particles containing high levels of prM after cell treatment 
with chloroquine  [72,73]. Apparently, infection enhancement and lack of potent neutralization are 
common  properties  of  anti-prM  antibodies,  suggesting  that  prM  constitutes  another  target  for 
infection-enhancing  antibodies  but  also  that  extracellular  dengue  virions  containing  prM  could  be 
infectious [18].  
Previous studies have shown that immature particles are non-infectious, since the presence of prM 
obstructs the low-pH-induced conformational changes in the E protein required for membrane fusion 
of the virus [15,74]. However, very recently, Rodenhuis-Zybert et al. [75] showed that fully immature 
dengue particles become highly infectious when interacting with prM antibodies. They showed that 
lack of infectivity of immature particles in the absence of antibodies was related to inefficient binding 
of immature virions to cell surfaces, but if binding is facilitated through anti-prM antibodies, immature 
particles become highly infectious, presumably due to efficient intracellular processing of prM to M by 
furin  activity  within the target  cell. These  antibodies  facilitate  efficient binding and cell entry by 
immature particles into Fc-R- expressing cells [75].  
Together, these observations suggest that immature viral particles have the potential to be highly 
infectious  and  hence  may  contribute  to  development  of  the  severe  disease  during  secondary  Viruses 2010, 2                         
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infection [75]. Consequently, it is important to define the possible in vivo effects of maintaining prM 
on the virion surface but also the viral and host factors involved in the efficiency of prM cleavage. It 
has  been  suggested  that  alteration  of  furin  target  sequence  in  the  prM  junction  can  affect  virus  
export  [76].  Also,  several  studies  have  suggested  that  the  multiplication  of  flaviviruses  is  not 
self-reliant  and  that  the  viruses  subvert  cellular  proteins  to  become  part  of  their  replication  
strategy [77,78]. 
Of interest is that Dejnirattisai et al. [1] found that antibodies to prM were a major component of 
the anti-dengue response. Previous reports recognized that the main response is directed to E protein, 
but also support that anti-prM antibodies are generated during dengue infection in humans [79–81]. It 
cannot be excluded that these apparently dissimilar observations depend on the characteristics of the 
tested samples and the employed methodologies. 
CryoEM images have shown that WNV and DENV preparations contain a mixture of immature, 
partially mature and mature viral particles, most likely due to incomplete processing by furin during 
maturation [82]. Cherrier et al. showed that an epitope within the fusion loop of WNV E protein is 
largely  inaccessible  in  mature  virions  but  that  a  cross-reactive  fusion-loop  antibody  with  low 
neutralization  activity  binds  preferentially  to  the  spikes  in  immature  virions  [82].  In  a  secondary 
infection,  these  antibodies  may  promote infection  through ADE  by augmenting attachment and/or 
entry of partially immature virions. The fact that an antibody neutralizes infectivity by binding to an 
immature virion supports the hypothesis that hybrid mature/immature particles can contribute to virus 
infectivity and pathogenesis [82]. These observations can also be extended to anti prM antibody. 
Figure 1 shows viral populations and anti-E and -prM antibodies involved in neutralization and 
ADE of DENV infection. 
Figure 1. Schematic representation of viral populations and anti-E and anti-prM antibodies 
involved  in  neutralization  and  ADE  mechanism.  Immature  ( ),  partially  mature  ( ),  
mature ( ) viral particles, neutralizing anti-E antibodies (Y), cross-reactive non-neutralizing 
anti-E antibodies (Y) and cross reactive anti-prM antibodies (Y).  
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6. Conclusions 
DHF/DSS is the result of the interaction of several factors in which the viral and host characteristics 
are important [44,83]. Some DENV genotypes have the potential to produce DHF [84]. In addition, 
host factors are of importance: these include age (children at higher risk than adults), ethnicity (white 
people at higher risk than black people), chronic diseases (bronchial asthma, diabetes mellitus, sickle 
cell anemia), nutritional status, sex and the individual’s genetic composition (allelic variants of genes 
that  encode  cellular  receptors  such  as  DC-SIGN  and  FcRIIA,  Vitamin  D  receptor  as  well  as 
molecules involved in the antigen recognition, HLA, and cytokines have also been associated with 
higher or lower risk of DHF) [85–91]. However, secondary infection is considered the main risk factor 
for disease severity.  
The dengue antibody somehow modulates subsequent infection with an enhancing or neutralizing 
role  that  up-  or  down-regulates  dengue  infection  of  mononuclear  phagocytes  (Figure  1)  [92]. 
Consistent with current evidence and considering ADE as a central mechanism, a working hypothesis 
of  dengue  pathogenesis  suggests  that  DHF/DSS  during  a  secondary  infection  is  the  result  of  
antibody-enhanced  infection  of  mononuclear  phagocytes.  Immune  complex  infection  suppresses 
cellular immune responses, increasing intracellular infection and generating inflammatory cytokines 
and chemokines that together contribute to the development of severe disease [48].  
Concern over ADE and its role in DHF/DSS suggest the necessity of a tetravalent dengue vaccine 
stimulating a balanced and long-lasting immune response to the four serotypes. The elegant work 
published  by  Dejnirattisai  et  al.  [1]  adds  new  information  to  our  knowledge  about  ADE,  calling 
attention  to  the  complexity of this  phenomenon  [1]. More  research is  needed  to  elucidate  ADE’s 
molecular mechanisms, particularly factors influencing the final outcome of the interaction among the 
virus, antibody and permissive cells. Among the issues meriting careful study are the interaction of 
anti-prM and -E antibodies with the infecting virus to neutralize or enhance infection, the factors 
determining the ratio of immature/mature virion particles, the influence of ADE complement levels, 
and the interaction with Fc-receptors [93–96].  
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